Search results
Results from the WOW.Com Content Network
Hy's law is a rule of thumb that a patient is at high risk of a fatal drug-induced liver injury if given a medication that causes hepatocellular injury (not Hepatobiliary injury) with jaundice. [1] The law is based on observations by Hy Zimmerman, a major scholar of drug-induced liver injury.
The FDA first warned in September that the drug could cause liver problems. It escalated that warning after reviewing the case of a person with blood markers of liver injury who had been taking ...
The US Food and Drug Administration (FDA) prescription label for the combination contains a boxed warning about drug-induced liver injury and liver failure. [1]
Drug-induced liver injury (DILI) is a cause of acute and chronic liver disease caused specifically by medications and the most common reason for a drug to be withdrawn from the market after approval. The liver plays a central role in transforming and clearing chemicals and is susceptible to the toxicity from these agents.
This month, the FDA granted accelerated approval to Iqirvo (elafibranor) for the treatment of an autoimmune disease that can affect the liver called primary biliary cholangitis. FDA Approves Drug ...
Gilead is also developing a drug for PBC, on which the FDA is expected to decide in August. ($1 = 0.9289 euros) (Reporting by Puyaan Singh and Mariam Sunny in Bengaluru; Editing by Krishna Chandra ...
The first reports of serious liver toxicity with nefazodone were published in 1998 and 1999. [40] [41] These instances were quickly followed by many additional cases. [42] [22] [23] [24] In 2002 the United States Food and Drug Administration (FDA) obligated BMS to add a black box warning about potential fatal liver toxicity to the drug label.
The US Food and Drug Administration has approved the first medication for a common form of liver inflammation called nonalcoholic steatohepatitis, or NASH, the agency said Thursday.